Active substance
Results for the substance mosunetuzumab
4 results
About this active substance
Mosunetuzumab is a monoclonal antibody used for the treatment of certain types of non-Hodgkin lymphoma, including relapsed or refractory follicular lymphoma. It works by activating T cells of the immune system to attack cancer cells.
The medication is administered via intravenous infusion and is used in cases where other treatments have failed. It is effective in reducing tumor size and prolonging patient survival.
Side effects may include cytokine release syndrome, fever, fatigue, nausea, and infections. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mosunetuzumab. This medication must be administered under the supervision of an oncology specialist.
The medication is administered via intravenous infusion and is used in cases where other treatments have failed. It is effective in reducing tumor size and prolonging patient survival.
Side effects may include cytokine release syndrome, fever, fatigue, nausea, and infections. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mosunetuzumab. This medication must be administered under the supervision of an oncology specialist.
-
-
LUNSUMIO 1mg concentrate for solution for infusion EGIS ORIGINAL MEDICINE
-
LUNSUMIO 5mg solution for injection EGIS ORIGINAL MEDICINE
-
LUNSUMIO 45mg solution for injection EGIS ORIGINAL MEDICINE